Eiger BioPharmaceuticals, Inc. financial data

Symbol
EIGRQ on OTC
Industry
Biological Products, (No Diagnostic Substances)
Location
2155 Park Boulevard, Palo Alto, CA
Fiscal year end
December 31
Former names
Celladon Corp (to 3/23/2016)
Latest financial report
10-K - Q4 2023 - Apr 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 235 % -54.3%
Quick Ratio 8.23 % -13.6%
Debt-to-equity 672 % +808%
Return On Equity -870 % -650%
Return On Assets -113 % -69.1%
Operating Margin -688 % -8.54%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.48M shares -96.6%
Common Stock, Shares, Outstanding 1.48M shares +0.7%
Entity Public Float 30M USD -89.1%
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 1.48M shares +6.39%
Weighted Average Number of Shares Outstanding, Diluted 1.48M shares +6.39%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 3.21M USD -20.3%
Cost of Revenue 115K USD -90.7%
Research and Development Expense 62.3M USD -17.2%
Costs and Expenses 87.6M USD -17.6%
Operating Income (Loss) -71.8M USD +22.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -75M USD +22.5%
Income Tax Expense (Benefit) 6K USD -73.9%
Net Income (Loss) Attributable to Parent -75M USD +22.5%
Earnings Per Share, Basic -50.8 USD/shares +27.2%
Earnings Per Share, Diluted -50.8 USD/shares +27.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 25.4M USD -1.39%
Cash, Cash Equivalents, and Short-term Investments 39.4M USD -67.4%
Inventory, Net 1.56M USD -45.5%
Assets, Current 37.8M USD -67.8%
Property, Plant and Equipment, Net 627K USD -9.91%
Operating Lease, Right-of-Use Asset 209K USD -15%
Other Assets, Noncurrent 360K USD -81.1%
Assets 38.8M USD -67.7%
Accounts Payable, Current 2.12M USD -76.4%
Accrued Liabilities, Current 9.97M USD -36.3%
Liabilities, Current 53.3M USD +112%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 53.3M USD -17.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -169K USD +43.7%
Retained Earnings (Accumulated Deficit) -512M USD -17.1%
Stockholders' Equity Attributable to Parent -14.5M USD -126%
Liabilities and Equity 38.8M USD -67.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -24M USD -30%
Net Cash Provided by (Used in) Financing Activities 41K USD -99.9%
Net Cash Provided by (Used in) Investing Activities 13.4M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 1.48M shares +0.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -10.6M USD -144%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 25.4M USD -1.39%
Interest Paid, Excluding Capitalized Interest, Operating Activities 920K USD +34.1%
Deferred Tax Assets, Valuation Allowance 117M USD +21.2%
Deferred Tax Assets, Gross 117M USD +21%
Operating Lease, Liability 205K USD -26.5%
Payments to Acquire Property, Plant, and Equipment 216K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -74.8M USD +22.8%
Lessee, Operating Lease, Liability, to be Paid 209K USD -26.4%
Property, Plant and Equipment, Gross 1.8M USD +12.9%
Operating Lease, Liability, Current 84K USD -82.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 84K USD -27%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure +43.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4K USD -20%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 69.4M USD +10.1%
Unrecognized Tax Benefits 5.28M USD +51.1%
Operating Lease, Payments 200K USD 0%
Depreciation, Depletion and Amortization 74K USD +1.37%
Deferred Tax Assets, Net of Valuation Allowance 21K USD -83.6%
Share-based Payment Arrangement, Expense 5.01M USD -39.8%
Interest Expense 5.47M USD +32.3%